This SPORE intends to build on M. D. Anderson's deep tradition of translational research and discovery in head and neck (HN) cancer therapy and chemoprevention to improve the basic understanding and clinical control of HN cancer. In response to our previous review, this revised application includes a new project, Project 1 (""""""""Intrinsic Apoptosis Phenotype and Susceptibility to Squamous Cell Carcinoma of the Oral Cavity""""""""), a significantly revised project (Project 3, previously numbered Project 2, """"""""Predictors of Resistance to Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer"""""""") and two projects that were previously well-reviewed, """"""""Cancer Risk Assessment in Patients with Oral Premalignant Lesions: An Integrative Approach"""""""" (now numbered as Project 2), and """"""""Targeting EGFR and the IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma"""""""" (Project 4). We will investigate associations between genetic variants, apoptotic capacity phenotypes, and oral cancer risk (Project 1). We will assess the host susceptibility, global and specific molecular aberrations in oral premalignant lesions and epidemiologic factors build a model of risk for oral carcinogenesis (Project 2). We will investigate novel molecular profiling methods to identify signatures associated with resistance to an agent that co-targeting EGFR and VEGFR (Project 3), and we will investigate co-targeting EGFR and insulin-like growth factor 1 receptor (IGF-1R) (Project 4) in order to improve on the clinical benefit already achieved by EGFR inhibitors (e.g., cetuximab) in HN cancer patients. The translational expertise/resources of our biostatistics (e.g., comprehensive methodologies and models for assessing multiple biomarkers) and pathology cores (e.g., cutting-edge tissue banking) are unsurpassed in the world. The past trial activation and accrual record of this HN SPORE was the appropriate target of criticism in our previous review;thus, the SPORE leadership team has implemented several mechanisms to enhance the oversight, and thus activation and accrual, of our SPORE clinical trials, as detailed throughout this revised application. M. D. Anderson Cancer Center has reaffirmed its extraordinary commitment to this SPORE renewal. SPORE PI Dr. Lippman led a rigorous review of previous SPORE projects and relevant new science as we designed, refined, and selected projects for this revised renewal application. With substantive changes made to our application and the strengths of an exceptional leadership team and outstanding resources, we believe this HN SPORE application now reflects the most exceptional constellation of SPORE components and investigators that we could propose.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097007-09
Application #
8119677
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Ujhazy, Peter
Project Start
2002-09-30
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
9
Fiscal Year
2011
Total Cost
$2,412,760
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Rui; Ding, Chunyong; Zhang, Jun et al. (2017) Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Res 77:3001-3012
Quinlan-Davidson, Sean R; Mohamed, Abdallah S R; Myers, Jeffrey N et al. (2017) Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol 72:90-97
Cardenas, Carlos E; Mohamed, Abdallah S R; Tao, Randa et al. (2017) Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys 98:532-540
Rosenthal, David I; Mohamed, Abdallah S R; Garden, Adam S et al. (2017) Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys 98:1002-1011
MD Anderson Head and Neck Cancer Symptom Working Group (2017) Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiother Oncol 124:232-239
Liu, Zhensheng; Liu, Hongliang; Han, Peng et al. (2017) Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. Eur J Cancer 72:166-176
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
MICCAI/M.D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group (2017) Matched computed tomography segmentation and demographic data for oropharyngeal cancer radiomics challenges. Sci Data 4:170077
Li, Jie; Mitani, Yohitsugu; Rao, Pulivarthi H et al. (2017) Establishment and genomic characterization of primary salivary duct carcinoma cell line. Oral Oncol 69:108-114
Zhu, Lijun; Sturgis, Erich M; Zhang, Hua et al. (2017) Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 141:1355-1364

Showing the most recent 10 out of 342 publications